Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board
Salarius Pharmaceuticals, Inc. (SLRX)
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass. and HOUSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide conjugate therapeutics, announces that Massachusetts Institute of Technology (MIT) Professor and Moderna co-founder Robert S. Langer, ScD will join the company’s Scientific Advisory Board (SAB) upon the successful completion of Decoy’s merger with Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX). As announced on January 13, 2025, Decoy and Salarius Pharmaceuticals signed a definitive agreement under which Decoy Therapeutics will merge with a wholly owned subsidiary of Salarius Pharmaceuticals, with the newly formed company to be named Decoy Therapeutics. Dr. Langer is a world-renowned scientist, entrepreneur and biotechnology visionary. His groundbreaking work in drug delivery systems design and in tissue engineering have earned him numerous awards, including the prestigious National Medal
Show less
Read more
Impact Snapshot
Event Time:
SLRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLRX alerts
High impacting Salarius Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SLRX
News
- Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual MeetingGlobeNewswire
- Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate PlatformGlobeNewswire
- Salarius Pharmaceuticals (NASDAQ:SLRX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- NanOlogy Appoints David J. Arthur as Chief Executive Officer to Drive Clinical Development of its Large Surface Area Microparticle (LSAM) Investigational Drug Portfolio [Yahoo! Finance]Yahoo! Finance
- Salarius Pharmaceuticals (NASDAQ:SLRX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
SLRX
Sec Filings
- 12/19/25 - Form DEFA14A
- 12/19/25 - Form 8-K
- 11/24/25 - Form 4
- SLRX's page on the SEC website